Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1 Receptor Agonists

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the type of gastric content and quantify the volume of liquid gastric contents using ultrasonography in patients on GLP-1 agonists that have presented for elective surgery and to determine if risk factors are associated with a higher gastric volume in patients on GLP-1 receptor agonists.

Official Title
-----------------
Gastric Ultrasound Assessment for Preoperative Prandial State of Patients Taking Glucagon-Like Peptide-1(GLP-1) Receptor Agonists

Conditions
-----------------
Pulmonary Aspiration

Intervention / Treatment
-----------------
* Diagnostic Test: Gastric ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients taking GLP-1receptor agonists (N=62) Patients not taking GLP-1 receptor agonists (N=62) Exclusion Criteria: Previous gastric resection or bypass Gastric band in situ Previous fundoplication Large hiatal hernia Pregnant patients Recent trauma Inability to turn to the right lateral decubitus position

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group G: Patients taking GLP-1receptor agonists<br> | Diagnostic Test: Gastric ultrasound<br>* Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.<br>|
| Group C: Patients not taking GLP-1 receptor agonists (control group)<br> | Diagnostic Test: Gastric ultrasound<br>* Patient will be scanned first in the supine position and then in the right lateral decubitus position. The ultrasound probe will be placed in a sagittal plane in the epigastric region at the left subcostal margin and then will be moved past the midline in a fan like manner to the right subcostal region. Qualitative and quantitative assessments will be done.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects that are at risk for aspiration | Risk for aspiration is indicated by the presence of solids, thick fluid, or clear fluids >1.5ml/kg in the gastric antrum in the right lateral decubitus position | end of ultrasound | 
| Number of subjects that are at low risk for aspiration | Low risk for aspiration is indicated by a collapsed gastric antrum or clear fluids <1.5ml/kg in the gastric antrum in the right lateral decubitus position. | end of ultrasound | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Age |  | end of ultrasound | 
| Number of participants that are male as indicated in the medical records |  | end of ultrasound | 
| Number of participants that are female as indicated in the medical records |  | end of ultrasound | 
| Body mass Index (BMI) | Body Mass Index (BMI) is calculated as the body mass in kilograms (kg) divided by the square of the body height in meters, and is expressed in units of kg/m2. | end of ultrasound | 
| Physical status as assessed by the American Society of Anesthesiologists (ASA) physical status classification system | The classification ranges from American Society of Anesthesiologists (ASA)1 (normal healthy person ) to ASA IV (A patient with severe systemic disease that is a constant threat to life) | end of ultrasound | 
| Number of participants with diabetes |  | end of ultrasound | 
| Number of participants with reported nothing by mouth (NPO) status |  | end of ultrasound | 
| Pain severity as assessed by the numeric scale | This is a 11 point scale with scores ranging from 0 (no pain) to 10 (worst imaginable pain) | end of ultrasound | 
| Number of participants with Gastroesophageal reflux disease (GERD) |  | end of ultrasound | 
| Number of participants that have use opioids preoperatively |  | end of ultrasound |